Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226M
-
Number of holders
-
164
-
Total 13F shares, excl. options
-
86.1M
-
Shares change
-
+1.44M
-
Total reported value, excl. options
-
$2.21B
-
Value change
-
+$36M
-
Put/Call ratio
-
1.93
-
Number of buys
-
65
-
Number of sells
-
-82
-
Price
-
$25.70
Significant Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q3 2021
205 filings reported holding ALLO - Allogene Therapeutics, Inc. - Common Stock as of Q3 2021.
Allogene Therapeutics, Inc. - Common Stock (ALLO) has 164 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 86.1M shares
of 226M outstanding shares and own 38.07% of the company stock.
Largest 10 shareholders include TPG Group Holdings (SBS) Advisors, Inc. (18.7M shares), BlackRock Inc. (7.27M shares), VANGUARD GROUP INC (6.7M shares), Capital Research Global Investors (5.4M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.34M shares), PRIMECAP MANAGEMENT CO/CA/ (3.6M shares), Capital International Investors (3.53M shares), STATE STREET CORP (3.51M shares), JPMORGAN CHASE & CO (3.32M shares), and ALLIANCEBERNSTEIN L.P. (3.22M shares).
This table shows the top 164 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.